Market Intelligence, Clinical Progress, and High-Purity Reagents for Alzheimer's Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for APP/Beta Amyloid drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | APP ECD / Beta Amyloid Peptides High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View APP Products |
| Pathogenic Mutant | APP Swedish Mutant (K670N/M671L) ECD-Fc / Aβ1-42 Peptide Theoretical MW confirmed. For amyloidogenic processing and aggregation kinetics. |
View APP Products |
| Gene Delivery | APP Promise-ORF / Lentivirus Full-length APP770 for stable cell lines. Compatible with Flow Cytometry / ELISA. |
View APP Products |
| Benchmark Ab | Anti-Beta Amyloid (Sequence of Lecanemab/Donanemab) Recombinant human IgG1 positive control. HEK293 expressed. |
View APP Products |
| Validator | APP siRNA Set For knockdown verification and specificity control in cell-based secretase assays. |
View APP Products |
| Related Target: MAPT | MAPT (Tau) Synergistic pathology network in Alzheimer's Disease. |
View MAPT Products |
| Related Target: TREM2 | TREM2 Microglial activation and plaque clearance regulation. |
View TREM2 Products |
| Related Target: TFRC | TFRC (TfR) Blood-Brain Barrier (BBB) transport for bispecific delivery. |
View TFRC Products |
| Related Target: BACE1 | BACE1 (β-Secretase 1) Rate-limiting protease in Aβ generation; central target for inhibitor screening and combination logic. |
View BACE1 Products |
| Related Target: PSEN1 | PSEN1 (Presenilin 1) Catalytic core of gamma-secretase; familial AD mutations validated. |
View PSEN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Specificity Mapping | Sequence-verified, high-purity peptides allowing for controlled aggregation (monomer vs oligomer assays). |
| Genetic Variant Cross-Reactivity | Familial mutation proteins (e.g., Swedish, Arctic, London) available with Theoretical MW verification. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) included with strictly controlled HEK293 expression. |
| False Positives in Cleavage Assays | Validated siRNA included for specificity checks and endogenous background reduction. |
| Human vs Rodent Aβ Sequence Divergence | Human-specific peptides with 3 aa differences from rodent; TarMart provides cross-species validation materials. |
Live APP/Beta Amyloid R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for APP/Beta Amyloid therapeutics has reached a historic turning point, with major players validating the amyloid hypothesis through monoclonal antibodies that successfully clear plaques and slow cognitive decline. As first-generation therapies reach the clinic and achieve regulatory milestones, the next wave of R&D is heavily targeting enhanced Blood-Brain Barrier (BBB) penetration via bispecific shuttles, safer effector function profiles to minimize Amyloid-Related Imaging Abnormalities (ARIA), and combinations with anti-Tau therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Biogen/Eisai, Eli Lilly | Early Alzheimer's Disease | Epitope Selectivity Assay (Need high-purity variant peptides) |
| Bispecific (BBB Shuttle) | Roche, Denali | Alzheimer's Disease | Transcytosis & Dual-Binding Validation (Need APP + TfR antigens) |
| Small Molecule (Gamma/BACE) | Various (Historical/Repurposing) | Preclinical AD | Cleavage Selectivity Assay (Need HEK293 Expressed APP ECD) |